Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) EPS (Basic) (2020 - 2025)

Historic EPS (Basic) for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to -$1.01.

  • 4D Molecular Therapeutics' EPS (Basic) fell 2784.81% to -$1.01 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.75, marking a year-over-year decrease of 3157.89%. This contributed to the annual value of -$2.98 for FY2024, which is 1558.7% down from last year.
  • According to the latest figures from Q3 2025, 4D Molecular Therapeutics' EPS (Basic) is -$1.01, which was down 2784.81% from -$0.98 recorded in Q2 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' EPS (Basic) peaked at -$0.24 during Q3 2023, and registered a low of -$1.01 during Q3 2025.
  • Its 5-year average for EPS (Basic) is -$0.76, with a median of -$0.82 in 2021.
  • In the last 5 years, 4D Molecular Therapeutics' EPS (Basic) surged by 9041.1% in 2021 and then plummeted by 22916.67% in 2024.
  • Quarter analysis of 5 years shows 4D Molecular Therapeutics' EPS (Basic) stood at -$0.85 in 2021, then increased by 1.18% to -$0.84 in 2022, then increased by 8.33% to -$0.77 in 2023, then fell by 19.58% to -$0.92 in 2024, then fell by 9.69% to -$1.01 in 2025.
  • Its EPS (Basic) was -$1.01 in Q3 2025, compared to -$0.98 in Q2 2025 and -$0.86 in Q1 2025.